An independent intelligence board aggregating credible research, preprints, clinical findings, biohacking experiments, and community discussions on therapeutic peptides, longevity science, and evidence-based anti-aging. Stories are scored for relevance, credibility, novelty, momentum, and practicality so the most important findings surface first.
Eli Lilly won approval to expand the official U.S. label for Mounjaro so the drug can now be marketed as reducing the risk of major heart problems. In plain terms: regulators reviewed data and agreed that people taking Mounjaro have a lower chance of bad heart events compared with people not taking it, so the company can say that on the label and in advertising. Mounjaro is the brand name for tirzepatide. It’s a man-made molecule that acts like two natural gut hormones that help control blood sugar and appetite. One hormone tells your body to release insulin when you eat; the other affects appetite and digestion. By mimicking both, the drug helps lower blood sugar and often causes weight loss. People have heard of similar drugs like Ozempic or Wegovy, which act on one of those hormones; Mounjaro targets both. The new approval is based on a large clinical trial designed to see whether people taking Mounjaro had fewer major cardiovascular events — things like heart attack, stroke, or cardiovascular death — than those on a comparison treatment. The study included many patients with type 2 diabetes who were already at increased heart risk. The result showed a statistically significant reduction in those major heart problems for the Mounjaro group. This was not a tiny pilot study; it was a big, controlled trial that met the standard regulators use to claim a heart benefit. This matters because heart disease is the leading cause of death for people with type 2 diabetes. If a diabetes drug also lowers heart risk, doctors can choose it not just to control blood sugar but to help protect the heart. Patients with diabetes and existing heart disease, or those at high risk, are the most likely to benefit from this new label. For some people this may change which medication their clinician recommends. There are still important caveats. The heart benefit applies to the kind of patients who were studied — mainly people with type 2 diabetes and elevated cardiovascular risk — so it may not automatically apply to everyone using the drug for weight loss or other reasons. Mounjaro can cause side effects like nausea, diarrhea, and sometimes more serious problems; long-term effects outside the trial population are still being monitored. Also, regulatory approval means the label can say Mounjaro reduces heart risk, but individual decisions about treatment should be made with a doctor who knows your health history. Bottom line: A large trial showed tirzepatide (Mounjaro) reduces major heart events in people with type 2 diabetes at risk of cardiovascular disease, and U.S. regulators have allowed the company to expand its label to reflect that benefit.
Source: Yahoo